Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabiralizumab + Nivolumab in Advanced Pancreatic Cancer
NCT03336216Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of cabiralizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Bristol Myers Squibb. Started Dec 2017; status: completed.
02
Drugs
cabiralizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03336216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336216.